Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41

Virology

Volumn 413, Issue 1, 2011, Pages 47-59

  Anastassopoulou, Cleo G ^a   Ketas, Thomas J ^a   Depetris, Rafael S ^a   Thomas, Antonia M ^a   Klasse, Per Johan ^a   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Entry inhibitors; Escape mutants; Fusion peptide; GPCR; HIV 1; Vicriviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HYBRID PROTEIN; VICRIVIROC; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953086675     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.12.052     Document Type: Article

References (34)

1. Agrawal-Gamse C., Lee F.H., Haggarty B., Jordan A.P., Yi Y., Lee B., Collman R.G., Hoxie J.A., Doms R.W., Laakso M.M. Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J. Virol. 2009, 83(21):11005-11015.
2. Anastassopoulou C.G., Marozsan A.J., Matet A., Snyder A.D., Arts E.J., Kuhmann S.E., Moore J.P. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 2007, 3(6):e79.
3. Anastassopoulou C.G., Ketas T.J., Klasse P.J., Moore J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(13):5318-5323.
4. Baba M., Miyake H., Wang X., Okamoto M., Takashima K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 2007, 51(2):707-715.
5. Berro R., Sanders R.W., Lu M., Klasse P.J., Moore J.P. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009, 5(8):e1000548.
6. Buzon V., Natrajan G., Schibli D., Campelo F., Kozlov M.M., Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6(5):e1000880.
7. Coffin J.M. HIV viral dynamics. Aids 1996, 10(Suppl 3):S75-84.
8. Dudley D.M., Wentzel J.L., Lalonde M.S., Veazey R.S., Arts E.J. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J. Virol. 2009, 83(10):5067-5076.
9. Hartley O., Klasse P.J., Sattentau Q.J., Moore J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 2005, 21(2):171-189.
10. Hirsch M.S., Gunthard H.F., Schapiro J.M., Brun-Vezinet F., Clotet B., Hammer S.M., Johnson V.A., Kuritzkes D.R., Mellors J.W., Pillay D., Yeni P.G., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top. HIV Med. 2008, 16(3):266-285.
11. Jaroniec C.P., Kaufman J.D., Stahl S.J., Viard M., Blumenthal R., Wingfield P.T., Bax A. Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry 2005, 44(49):16167-16180.
12. Ketas T.J., Kuhmann S.E., Palmer A., Zurita J., He W., Ahuja S.K., Klasse P.J., Moore J.P. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007, 364(2):281-290.
13. Klasse P.J. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 2007, 369(2):245-262.
14. Kuhmann S.E., Hartley O. Targeting chemokine receptors in HIV: a status report. Annu. Rev. Pharmacol. Toxicol. 2008, 48:425-461.
15. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., Strizki J.M., Riley J., Baroudy B.M., Wilson I.A., Korber B.T., Wolinsky S.M., Moore J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78(6):2790-2807.
16. Laakso M.M., Lee F.H., Haggarty B., Agrawal C., Nolan K.M., Biscone M., Romano J., Jordan A.P., Leslie G.J., Meissner E.G., Su L., Hoxie J.A., Doms R.W. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007, 3(8):e117.
17. Lin G., Bertolotti-Ciarlet A., Haggarty B., Romano J., Nolan K.M., Leslie G.J., Jordan A.P., Huang C.C., Kwong P.D., Doms R.W., Hoxie J.A. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J. Virol. 2007, 81(18):9956-9966.
18. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., Baroudy B.M., Strizki J., Moore J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338(1):182-199.
19. Murray E.J., Leaman D.P., Pawa N., Perkins H., Pickford C., Perros M., Zwick M.B., Butler S.L. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J. Virol. 2010, 84(14):7288-7299.
20. Nolan K.M., Jordan A.P., Hoxie J.A. Effects of partial deletions within the human immunodeficiency virus type 1V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J. Virol. 2008, 82(2):664-673.
21. Nolan K.M., Del Prete G.Q., Jordan A.P., Haggarty B., Romano J., Leslie G.J., Hoxie J.A. Characterization of a human immunodeficiency virus type 1V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J. Virol. 2009, 83(8):3798-3809.
22. Ogert R.A., Wojcik L., Buontempo C., Ba L., Buontempo P., Ralston R., Strizki J., Howe J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373(2):387-399.
23. Ogert R.A., Hou Y., Ba L., Wojcik L., Qiu P., Murgolo N., Duca J., Dunkle L.M., Ralston R., Howe J.A. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400(1):145-155.
24. Pfaff J.M., Wilen C.B., Harrison J.E., Demarest J.F., Lee B., Doms R.W., Tilton J.C. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J. Virol. 2010, 84(13):6505-6514.
25. Platt E.J., Shea D.M., Rose P.P., Kabat D. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J. Virol. 2005, 79(7):4357-4368.
26. Platt E.J., Kozak S.L., Durnin J.P., Hope T.J., Kabat D. Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J. Virol. 2010, 84(6):3106-3110.
27. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361(1):212-228.
28. Qiang W., Weliky D.P. HIV fusion peptide and its cross-linked oligomers: efficient syntheses, significance of the trimer in fusion activity, correlation of beta strand conformation with membrane cholesterol, and proximity to lipid headgroups. Biochemistry 2009, 48(2):289-301.
29. Qiang W., Bodner M.L., Weliky D.P. Solid-state NMR spectroscopy of human immunodeficiency virus fusion peptides associated with host-cell-like membranes: 2D correlation spectra and distance measurements support a fully extended conformation and models for specific antiparallel strand registries. J. Am. Chem. Soc. 2008, 130(16):5459-5471.
30. Salzwedel K., Berger E.A. Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. Retrovirology 2009, 6:75.
31. Tilton, J.C., Wilen, C.B., Didigu, C.A., Sinha, R., Harrison, J.E., Agrawal-Gamse, C., Henning, E.A., Bushman, F.D., Martin, J.N., Deeks, S.G., Doms, R.W., 2010. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84 (20), 10863-10876.
32. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., Pugach P., Xu S., Wojcik L., Tagat J., Palani A., Shapiro S., Clader J.W., McCombie S., Reyes G.R., Baroudy B.M., Moore J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(1):395-400.
33. Tsibris A.M., Sagar M., Gulick R.M., Su Z., Hughes M., Greaves W., Subramanian M., Flexner C., Giguel F., Leopold K.E., Coakley E., Kuritzkes D.R. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 2008, 82(16):8210-8214.
34. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81(5):2359-2371.